title: Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
abstract: Concentrations of dapsone, monoacetyldapsone, and pyrimethamine were determined in 36 serum samples from human immunodeficiency virus-infected patients on prophylaxis with once-weekly administration of dapsone-pyrimethamine (200 mg of dapsone-75 mg of pyrimethamine). During day 1 after ingestion, median levels of 1,038 ng of dapsone per ml and 356 ng of pyrimethamine per ml were found. During days 6 to 7, the dapsone level fell to < 20 ng/ml in five of nine serum samples, but the pyrimethamine level remained elevated (125 ng/ml). Concurrent, but separately ingested, didanosine administration did not seem to decrease the drug concentrations.
authors.affiliation: Division of Infectious Diseases, University Hospital, Zurich, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Opravil
authors.forename: B
authors.initials: B
authors.lastname: Joos
authors.forename: R
authors.initials: R
authors.lastname: Lüthy
mesh_terms: D000328:Adult; D000368:Aged; D003622:Dapsone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood* / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use*; D016781:Toxoplasmosis, Cerebral / Q000517:prevention & control*; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015215:Zidovudine; D003622:Dapsone; C018965:monoacetyldapsone; D011739:Pyrimethamine